Drug Type Small molecule drug |
Synonyms (S)-2-aminobutanedioic acid, (S)-2-aminosuccinic acid, 2-Aminosuccinic acid + [6] |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (01 Jan 1996), |
Regulation- |
Molecular FormulaC4H7NO4 |
InChIKeyCKLJMWTZIZZHCS-REOHCLBHSA-N |
CAS Registry56-84-8 |
Start Date15 Sep 2023 |
Start Date01 Oct 2022 |
Sponsor / Collaborator |
Start Date01 Mar 2021 |
Sponsor / Collaborator |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Arrhythmias, Cardiac | CN | 01 Jan 1996 | |
Eczema | CN | 01 Jan 1996 | |
Heart Failure | CN | 01 Jan 1996 | |
Hepatitis, Viral, Human | CN | 01 Jan 1996 | |
Hypokalemia | CN | 01 Jan 1996 | |
Myocardial Infarction | CN | 01 Jan 1996 | |
Urticaria | CN | 01 Jan 1996 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Not Applicable | 440 | Usual Care (UC) | dfodtjtren(iqrnuqlgni) = iqfdqagvee ogtaalyjyd (giqltctdpg, nddllyevly - rfjkzcbebo) View more | - | 07 Nov 2023 | ||
Phase 3 | 1,645 | Quality-of-Life Assessment+Etoposide+Mitoxantrone Hydrochloride+Asparaginase+Cytarabine+Daunorubicin Hydrochloride (Arm A) | zwkdpolrmt(ustndpeied) = yjapohusmh phijnzzwxc (jrqbygapis, arloaimdai - mscediheox) View more | - | 07 Jul 2020 | ||
Quality-of-Life Assessment+Etoposide+Mitoxantrone Hydrochloride+Asparaginase+bortezomib+Cytarabine+Daunorubicin Hydrochloride (Arm B) | zwkdpolrmt(ustndpeied) = qepeobpswh phijnzzwxc (jrqbygapis, gkvnehqrgb - waxkdjdtdm) View more |